Rimegepant sulfate

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H373：Kann die Organe schädigen bei längerer oder wiederholter Exposition.

• Sicherheit

  P260：Dampf/Aerosol/Nebel nicht einatmen.

  P314：Bei Unwohlsein ärztlichen Rat einholen / ärztliche Hilfe hinzuziehen.

  P501：Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Rimegepant sulfate Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Rimegepant sulfate is a small molecule, highly selective calcitonin gene-related peptide antagonist (CGRP) developed by Biohaven Pharmaceutical Holdings, Inc. and approved by the FDA for the acute treatment of migraine. rimegepant and ubrogepant are the only CGRP antagonists with oral bioavailability. Because of the absence of vasoconstrictive properties observed with oral CGRP antagonists, the use of rimegepant is safer and more reliable in patients with contraindications to standard therapy^[1].

• Nebenwirkungen

  Common side effects of Rimegepant sulfate are nausea, which may be severe enough to cause shortness of breath, difficulty breathing; swelling of the face, eyes, mouth, throat, tongue, or lips; rash, measles; and itching.

• Synthese

  Rimegepant sulfate is prepared by the reaction of rimegepant and water.
  Step: With sulfuric acid In ethanol at 20 - 70℃; Solvent; Temperature.
  
  

• Einzelnachweise

  [1] J S. Rimegepant: First Approval.[J]. Drugs, 2020, 80 7: 741-746. DOI:10.1007/s40265-020-01301-3.

Rimegepant sulfate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(77)Suppliers